Table 5.
I-131 tositumomab | Y-90 ibritumomab tiuxetan | |
---|---|---|
Number of patients | 40 | 54 |
Median age of patients, years | 57 | 54 |
Median number prior therapies | 4 | 4 |
≥High-intermediate IPI score, % | 21 | 19 |
Rituximab “refractory”, % | 88 | 100 |
Percent with a tumour ≥5 cm, % | 50 | 74 |
Percent with a tumour ≥7 cm, % | 32 | 44 |
Bone marrow involved, % | 32 | 32 |
Response rate, % | 65 | 74 |
Median progression-free survival, months | 10.4 | 6.8 |
Complete response rate, % | 38 | 16 |
IPI, international prognostic index; LDH, lactate dehydrogenase